SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001072613-22-000412
Filing Date
2022-05-10
Accepted
2022-05-10 17:05:16
Documents
1
Group Members
ARCH VENTURE FUND IX OVERAGE, L.P.ARCH VENTURE PARTNERS IX OVERAGE, L.P.ARCH VENTURE PARTNERS IX, L.P.ARCH VENTURE PARTNERS IX, LLCCLINTON BYBEEKEITH CRANDELLROBERT NELSEN

Document Format Files

Seq Description Document Type Size
1 ARCH VENTURE FUND IX, L.P. -- VIR BIOTECHNOLOGY, INC. -- SCHEDULE 13DA(#5) archix-vir.htm SC 13D/A 282340
  Complete submission text file 0001072613-22-000412.txt   284158
Mailing Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631
Business Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 773-380-6600
ARCH Venture Fund IX, L.P. (Filed by) CIK: 0001666306 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 499 ILLINOIS STREET SUITE 500 SAN FRANCISCO CA 94158
Business Address 499 ILLINOIS STREET SUITE 500 SAN FRANCISCO CA 94158 415-906-4324
Vir Biotechnology, Inc. (Subject) CIK: 0001706431 (see all company filings)

IRS No.: 812730369 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91177 | Film No.: 22910875
SIC: 2836 Biological Products, (No Diagnostic Substances)